Oats: cooling inflammation and unhealthy cell proliferation.
Oats (Nutritional aspects)
|Author:||Bliss, Rosalie Marion|
|Publication:||Name: Agricultural Research Publisher: U.S. Government Printing Office Audience: Academic; General Format: Magazine/Journal Subject: Agricultural industry; Biotechnology industry; Business Copyright: COPYRIGHT 2010 U.S. Government Printing Office ISSN: 0002-161X|
|Issue:||Date: Feb, 2010 Source Volume: 58 Source Issue: 2|
|Topic:||Event Code: 310 Science & research|
|Product:||Product Code: 0119400 Oats; 8520110 Scientists NAICS Code: 11119 Other Grain Farming; 54171 Research and Development in the Physical, Engineering, and Life Sciences SIC Code: 0119 Cash grains, not elsewhere classified|
|Geographic:||Geographic Scope: United States Geographic Code: 1USA United States|
Health-conscious consumers long have chosen meals that include
oats--in part due to a snappy "heart healthy" claim that
prominently appears on the labels of packaged oat products sold
nationwide. Significantly, ARS-funded scientists have not only
discovered that certain compounds in oats hinder the ability of blood
cells to stick to artery walls, but they have also found further
indicators that the same compounds hold promise to provide other health
This research is led by nutritionist Mohsen Meydani, director of the Vascular Biology Laboratory at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University (HNRCA) in Boston, Massachusetts. Meydani previously showed that phenolic antioxidants in oats actually obstruct the ability of blood cells to stick to artery walls. He showed that the compounds, called "avenanthramides," from oats significantly suppress the adhesive molecules that glue blood cells to artery walls.
Now, Meydani has been working on determining the anti-inflammatory and other effects of oat avenanthramides and their derivatives. He is using several animal models and colon cancer cell lines for testing purposes. As a result of using these models, Meydani has published several journal articles that shed light on the compounds' potencies and molecular mechanisms.
A 2006 study published in the journal Free Radical Biology & Medicine demonstrated for the first time that avenanthramide-c arrests smooth muscle cell (SMC) proliferation, which is known to participate in arterial lesion development. Unhealthy SMC growth contributes to the development of atherosclerosis, which can eventually lead to heart attack. Also, vascular endothelial cells, and to a lesser degree SMCs, are involved in the synthesis of heart-healthy nitric oxide. The researchers found that avenanthramide-c treatment of human SMC significantly and dose-dependently increased nitric oxide production in both SMC and endothelial cells.
These results suggest that the avenanthramides of oats may contribute to the relaxation of arteries and the prevention of atherosclerosis by increasing nitric oxide production and inhibiting SMC proliferation. In fact, earlier human clinical studies conducted by Meydani's colleagues at the HNRCA have shown that consumption of oats reduces blood pressure.
Another 2008 study, also published in Free Radical Biology & Medicine, reported findings that suggest that avenanthramides decrease expression of inflammatory molecules. Because chronic inflammation of the arterial wall is part of the process that eventually causes disease, inhibition of inflammation through diet, drugs, or key nutrients is considered to be of great benefit in preventing atherosclerosis.
Findings from a more recent study soon to be published suggest that consuming oats and oat bran may reduce the risk of colon cancer, not only through high fiber content, but also through avenanthramides that slow or discourage proliferation of colon cancer cells.
These studies provide additional indications of the potential health benefit of oat consumption in the prevention of coronary heart disease beyond its known effect through lowering blood cholesterol.--By Rosalie Marion Bliss, ARS.
This research is part of Human Nutrition, an ARS national program (#107) described at www.nps.ars.usda.gov.
Mohsen Meydani is with the USDA-ARS Vascular Biology Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, 711 Washington St., Boston, MA 02111-1524; (617) 556-3126, mohsen.meydani@tufts. edu.
|Gale Copyright:||Copyright 2010 Gale, Cengage Learning. All rights reserved.|